

# CITATION REPORT

List of articles citing

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study

DOI: 10.1136/bmj.j1065  
BMJ, The, 2017, 356, j1065.

**Source:** <https://exaly.com/paper-pdf/68063058/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
142	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <b>2017</b> , 7, 16950		5
141	Stopping anticoagulation in a woman with unprovoked venous thromboembolism. <b>2017</b> , 189, E1112-E1114		2
140	[Anticoagulation after an acute pulmonary embolism]. <b>2017</b> , 46, 728-738		1
139	External validation of the DASH prediction rule: a retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 1963-1970	15.4	40
138	Preventing recurrence from distal deep vein thrombosis: Still searching for answers. <b>2017</b> , 22, 525-526		
137	The authors respond to "Thrombophilia testing in venous thromboembolism". <b>2018</b> , 190, E172		1
136	The year 2017 in cardiology: aorta and peripheral circulation. <i>European Heart Journal</i> , <b>2018</b> , 39, 730-738	9.5	5
135	Towards harmonization of external quality assessment/proficiency testing in hemostasis. <b>2018</b> , 57, 115-126		6
134	Service evaluation project - Are local recommendations for onward referral to a specialist menopause clinic required to translate guidelines into practice?. <b>2018</b> , 24, 83-96		
133	Anticoagulation Beyond 3 to 6Months: What Does the Data Tell Us?. <b>2018</b> , 60, 607-612		
132	New Trends in Anticoagulation Therapy. <b>2018</b> , 98, 219-238		15
131	Pulmonary embolism: Care standards in 2018. <b>2018</b> , 60, 613-621		10
130	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <b>2018</b> , 163, 41-46		27
129	Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	24
128	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <b>2018</b> , 162, 104-109		17
127	Breadth of complications of long-term oral anticoagulant care. <b>2018</b> , 2018, 432-438		3
126	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. <b>2018</b> , 11, 265-276		1

125	Anticoagulating patients with high-risk acquired thrombophilias. <b>2018</b> , 132, 2219-2229		8
124	D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. <b>2018</b> , 55, 548-577		61
123	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. <b>2018</b> , 27,		9
122	Actualité sur les D-dimères. <b>2018</b> , 29, 15-18		
121	Update on diagnosis and anticoagulant therapy for venous thromboembolism. <b>2018</b> , 48, 1175-1184		6
120	Update on extended treatment for venous thromboembolism. <b>2018</b> , 50, 666-674		14
119	Venous Thromboembolism: Advances in Diagnosis and Treatment. <b>2018</b> , 320, 1583-1594		128
118	Venous thromboembolism and women's health. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 346-363	4.5	16
117	Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 689-695	5.1	6
116	Who should get long-term anticoagulant therapy for venous thromboembolism and with what?. <b>2018</b> , 2018, 426-431		4
115	Anticoagulating patients with high-risk acquired thrombophilias. <b>2018</b> , 2018, 439-449		3
114	Who should get long-term anticoagulant therapy for venous thromboembolism and with what?. <b>2018</b> , 2, 3081-3087		8
113	Pulmonary embolism. <b>2018</b> , 4, 18028		128
112	The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy. <b>2018</b> , 26, 670-682		1
111	The Management of Venous Thromboembolic Disease: New Trends in Anticoagulant Therapy. <b>2018</b> , 52, 43-56		1
110	[What is the treatment duration after a venous thromboembolic event?]. <b>2018</b> , 39, 839-841		
109	Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism - Coming to consensus when the debate rages on. <b>2018</b> , 23, 384-387		4
108	Updates in venous thromboembolism management: evidence published in 2017. <b>2018</b> , 46, 183-188		1

107	Venous Thromboembolism: Role of the Clinical Laboratory in Diagnosis and Management. <b>2019</b> , 3, 870-882		11
106	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2019</b> , 366, l4363	5.9	83
105	Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). <b>2019</b> , 16, e1002883		15
104	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	413
103	Sex matters: Practice 5P's when treating young women with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1417-1429	15.4	16
102	Risk prediction of recurrent venous thrombosis; where are we now and what can we add?. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1527-1534	15.4	5
101	What have we learned from coagulation laboratory participation in external quality programs?. <b>2019</b> , 41 Suppl 1, 49-55		2
100	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1144-1152	15.4	21
99	Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment. <b>2019</b> , 21, 24		2
98	Venous thromboembolism: A clinician update. <b>2019</b> , 24, 122-131		12
97	Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. <b>2019</b> , 24, 141-152		4
96	Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE-Results from the ExACT randomised controlled trial. <b>2019</b> , 17, 100218		2
95	Utility of the DASH score after unprovoked venous thromboembolism; a single centre study. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 631-633	4.5	7
94	Six months two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial. <b>2019</b> , 104, 1493-1501		14
93	Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. <b>2019</b> , 105, 545-552		16
92	Prevention and Treatment of Venous Thromboembolism. <b>2019</b> , 273-299		1
91	Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis. <b>2020</b> , 26, 7-17		2
90	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , <b>2020</b> , 41, 543-603	9.5	1043

89	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. <b>2020</b> , 15, 453-462		7
88	A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study). <i>British Journal of Haematology</i> , <b>2020</b> , 188, 962-975	4.5	12
87	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <b>2020</b> , 4, 4693-4738		187
86	Epidemiology and 3-year outcomes of combined oral contraceptive-associated distal deep vein thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 1216-1223	5.1	1
85	Women's health in : a data science history. <b>2020</b> , 10, e039759		3
84	Predicting risk indices of recurrence in the unprovoked venous thromboembolic disease. <b>2020</b> , 155, 538-540		
83	Duration of anticoagulant therapy after pulmonary embolism can be a tough decision. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 617-618	0.7	0
82	Web Exclusive. Annals for Hospitalists Inpatient Notes - Can I Withdraw Anticoagulants in This Patient With Prior Venous Thromboembolism?. <b>2020</b> , 172, HO2-HO3		1
81	Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?. <b>2020</b> , 9, e019395		5
80	Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?. <b>2020</b> , 4, 5595-5606		5
79	Does age-adjusted D-dimer have a role in assessment of VTE recurrence rates? Comment. <b>2020</b> , 42, e240-e242		1
78	Pulmonary embolism: update on management and controversies. <i>BMJ, The</i> , <b>2020</b> , 370, m2177	5.9	30
77	What will happen in the future? A personal VTE journey. <b>2020</b> , 1, 100013		
76	Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?. <b>2020</b> , 2020, 201-212		2
75	Duration of Anticoagulant Therapy After Pulmonary Embolism Can Be a Tough Decision. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 617-618	0.7	
74	Does age-adjusted D-Dimer have a role in assessment of VTE recurrence rates?. <b>2020</b> , 42, 450-452		
73	Treatment of Acute Venous Thromboembolism. <b>2020</b> , 104, 631-646		
72	Long term use of anticoagulant therapy for patients with pulmonary embolism. <b>2020</b> , 13, 709-718		

71	Bilan de thrombophilie. <b>2020</b> , 2020, 26-33			1
70	From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis. <b>2020</b> , 21,			13
69	La femme est-elle plus à risque de maladie veineuse thromboembolique?. <b>2020</b> , 1, 180-184			
68	Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial. <b>2020</b> , 17, e1003142			6
67	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. <b>2020</b> , 25, 210-217			2
66	Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. <b>2020</b> , 135, 1377-1385	22		
65	Long-term treatment of venous thromboembolism. <b>2020</b> , 135, 317-325			21
64	How I treat obese patients with oral anticoagulants. <b>2020</b> , 135, 904-911			10
63	Prevention and Management of the Post-Thrombotic Syndrome. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1		19
62	An international survey of clinicians regarding their management of venous thromboembolism following the initial 3-6 months of anticoagulation. <b>2021</b> , 51, 17-24			2
61	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 30-40	15.4		1
60	Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: A French prospective cohort. <b>2021</b> , 84, 24-31			2
59	Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <b>2021</b> , 61, 9-82			69
58	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. <b>2021</b> , 77, 629-656			45
57	Decision-Making in the Management of Venous Thromboembolism. <b>2021</b> , 134, 317-325			
56	[What duration of anticoagulant treatment for PE/proximal DVT?]. <b>2021</b> , 38 Suppl 1, e99-e112			
55	Utility of a recurrence prediction tool (DASH score) at a single centre after unprovoked venous thromboembolism: patient uptake of the tool and short term risks of stopping anticoagulation. <b>2021</b> , 52, 971-973			
54	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. <b>2021</b> , 42, 218-232			

53	Venous thrombosis and predictors of relapse in eosinophil-related diseases. <b>2021</b> , 11, 6388		6
52	Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal. <b>2021</b> , 199, 85-96		2
51	Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8). <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 655226	5.4	1
50	Diagnostic accuracy of D-Dimer testing for recurrent venous thromboembolism: A systematic review with meta-analysis.: VTE recurrence and D-dimer. <b>2021</b> , 89, 39-47		3
49	D-dimer testing after anticoagulant discontinuation to predict recurrent venous thromboembolism. <b>2021</b> , 89, 25-26		1
48	Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism. <b>2021</b> , 1		0
47	Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk. <b>2021</b> , 129, 210-220		
46	Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. <i>TH Open</i> , <b>2021</b> , 5, e338-e342	2.7	2
45	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	1
44	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2801-2813	15.4	1
43	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <b>2021</b> , 174, 1420-1429		7
42	Direct oral anticoagulant dose selection: Challenging cases. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2680-2686	15.4	0
41	Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. <i>Hemato</i> , <b>2021</b> , 2, 64-78	0.2	0
40	Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2021</b> , 47, 692-701	5.3	5
39	[Contemporary approaches to determine the duration of anticoagulant therapy for venous thromboembolism]. <i>Khirurgiya</i> , <b>2019</b> , 94-103	0.6	4
38	Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
37	The year 2017 in cardiology: aorta and peripheral circulation. <i>Cardiologia Croatica</i> , <b>2018</b> , 13, 99-109	0	1
36	The Optimal Duration and Selection of Anti-coagulants after First Episode of Unprovoked Venous Thromboembolism. <i>Clinical &amp; Experimental Thrombosis and Hemostasis</i> , <b>2018</b> , 4, 1-6	0	

35	Extended therapy and secondary prevention of venous thromboembolic complications. <i>I P Pavlov Russian Medical Biological Herald</i> , <b>2020</b> , 28, 548-566	0.4	
34	Predicting risk indices of recurrence in the unprovoked venous thromboembolic disease. <i>Medicina Clínica</i> , <b>2020</b> , 155, 538-540	1	
33	Post-PE Management. <i>Respiratory Medicine</i> , <b>2020</b> , 153-180	0.2	
32	Clinical Application of D-Dimer in Venous Thromboembolism. <i>Annals of Phlebology</i> , <b>2020</b> , 18, 4-7	0.1	0
31	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , <b>2020</b> , 4, e446-e456	2.7	1
30	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and with the European Respiratory Society. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	7
29	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	0
28	Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism. Results from the REVERSE study. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	
27	[Diagnosis and treatment of pulmonary embolism]. <i>Herz</i> , <b>2021</b> , 46, 589-604	2.6	0
26	Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration. <i>Current Pharmaceutical Design</i> , <b>2021</b> ,	3.3	3
25	Biological Biomarkers in Respiratory Diseases.. <i>Archivos De Bronconeumologia</i> , <b>2022</b> ,	0.7	0
24	Risk of recurrence in women with venous thromboembolism related to oestrogen-containing contraceptives: systematic review and meta-analysis.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	0
23	Analytical performance of a new immunoturbidimetric D-dimer assay and comparison with available assays.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12660	5.1	2
22	[Translated article] Biological Biomarkers in Respiratory Diseases.. <i>Archivos De Bronconeumologia</i> , <b>2022</b> ,	0.7	2
21	Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a post-hoc analysis of a French prospective multicenter study.. <i>European Respiratory Journal</i> , <b>2022</b> ,	13.6	0
20	The utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis.. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2022</b> ,	3.2	
19	Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 830010	5.4	
18	Pulmonary embolism management in the emergency department.. <i>Emergency Medicine Journal</i> , <b>2022</b> ,	1.5	0



17	Hereditary Thrombophilia Testing Among Hospitalized Patients: Is It Warranted?. <i>Cureus</i> , <b>2022</b> ,	1.2	
16	Extended Anticoagulation for Venous Thromboembolism: A Survey of the American Venous Forum and the European Venous Forum.. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2022</b> ,	3.2	
15	Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.. <i>American Journal of Cardiovascular Drugs</i> , <b>2022</b> ,	4	○
14	Venous diseases including thromboembolic phenomena. <b>2022</b> , 377-390		
13	Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis. <i>British Journal of Haematology</i> ,	4.5	○
12	Pulmonary Embolism. <b>2022</b> , 387, 45-57		1
11	How Would You Treat This Patient With Pulmonary Embolism?. <b>2022</b> , 175, 1161-1169		
10	A ten-year review of the impact of the transition from warfarin to direct oral anticoagulant [Has venous thromboembolism treatment become safer?. <b>2022</b> , 219, 112-120		○
9	Risk of recurrent venous thromboembolism in selected subgroups of men: a Danish nationwide cohort study.		1
8	Deep Venous Thrombosis. <b>2022</b> , 175, ITC129-ITC144		○
7	Venous Thromboembolism Issues in Women. <b>2022</b> , 42, 290-299		○
6	Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account?. <b>2023</b> , 12, 22-31		○
5	Venous thromboembolism associated with estrogen-containing contraceptives versus any hormonal risk factor: a comparison of recurrence rates. <b>2023</b> , 21, 175-178		○
4	Massive DVT from the proximal IVC to the pedal vein: Our approach using aspiration mechanical thrombectomy and open surgery thrombectomy. <b>2023</b> , 18, 1830-1837		○
3	Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. <b>2023</b> , 6, 4-24		○
2	D-dimer testing: A narrative review. <b>2023</b> ,		○
1	Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis. 10,		○